Expert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi study

Basit Öğe Kaydı
dc.authoridYanık Odabaş, Özge/0000-0002-1822-8703
dc.authoridafrashi, filiz/0000-0001-6359-1600
dc.authoridKarabas, Levent/0000-0001-7860-4603
dc.authorscopusid6701581296
dc.authorscopusid56305645500
dc.authorscopusid7005998004
dc.authorscopusid6602831040
dc.authorscopusid6603753886
dc.authorscopusid56147066300
dc.authorscopusid57831304100
dc.authorwosidYanık Odabaş, Özge/AAO-6777-2020
dc.authorwosidafrashi, filiz/ABB-6647-2020
dc.contributor.authorBatioglu, Figen
dc.contributor.authorYanik, Ozge
dc.contributor.authorSaatci, Ali Osman
dc.contributor.authorEldem, Bora
dc.contributor.authorAkkin, Cezmi
dc.contributor.authorAfrashi, Filiz
dc.contributor.authorOzdemir, Hakan
dc.date.accessioned2023-01-12T20:04:00Z
dc.date.available2023-01-12T20:04:00Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPurpose To provide consensus on the clinical use of intravitreal dexamethasone (DEX) implant for the treatment of diabetic macular edema (DME) in Turkey. Methods A panel of 22 retina experts prepared 77 statements of recommendation, and 80 retinal specialists practicing in Turkey were chosen to vote either in support or against each one. A Delphi-based method was used through which the ophthalmologists were able to view all of the results anonymously after two rounds and modify their subsequent answers. The survey was conducted via a mini website, and statements without consensus were resent to the specialists with the latest vote results a week later. Results A total of 72 ophthalmologists answered the first and second round questions. After the first stage, consensus was achieved on 55 of the statements, leaving 22 without agreement. After the second stage, consensus was reached on 11 of the remaining statements. Strong consensus was achieved on statements regarding the etiopathogenesis of DME and the first-line indications and safety of the DEX implant procedure. The panel recommended the use of DEX implant for patients with an arterial thromboembolic event in the last three months and also agreed that pro re nata DEX implant treatment not only provides better outcomes for DME patients but also reduces the treatment burden for those who could not receive an adequate number of anti-vascular endothelial growth factor (VEGF) injections. Conclusion This study provides clinical consensus and recommendations about the use of DEX implant in the clinical practice of DME management in Turkey.en_US
dc.identifier.doi10.1177/11206721221117695
dc.identifier.issn1120-6721
dc.identifier.issn1724-6016
dc.identifier.pmid35924358en_US
dc.identifier.scopus2-s2.0-85135487512en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1177/11206721221117695
dc.identifier.urihttps://hdl.handle.net/11454/77749
dc.identifier.wosWOS:000835930000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofEuropean Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDelphi consensusen_US
dc.subjectdexamethasone implanten_US
dc.subjectdiabetic macular edemaen_US
dc.subjectGrowth-Factor Therapyen_US
dc.subjectRanibizumaben_US
dc.subjectAflibercepten_US
dc.subjectLaseren_US
dc.subjectTriamcinoloneen_US
dc.subjectRetinopathyen_US
dc.subjectPrevalenceen_US
dc.subjectConversionen_US
dc.subjectTrialen_US
dc.titleExpert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu